RxDoctor Payments Data

Honglan Lu, MD

Family Medicine · Grand Junction, CONPI 1437294287

Payments from drug & device makers

$3,686in general payments, 2019–2025

Across 126 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AbbVie$623
  • AstraZeneca$400
  • Exact Sciences$196
  • Astellas Pharma US Inc$169
  • Sumitomo Pharma America, Inc.$124
  • plus $379 from 9 others

What the payments were for

  • Food & beverage$3,59798%
  • Education$892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,686 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$136,204
Medicare patients
46
Services billed
2,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$57,146
EliquisApixaban52$36,160
GemtesaVibegron47$31,033
TrulicityDulaglutide17$23,929
JardianceEmpagliflozin20$14,788
JanuviaSitagliptin Phosphate12$14,512
EntrestoSacubitril/Valsartan19$13,823
FarxigaDapagliflozin Propanediol19$13,256
LinzessLinaclotide12$8,641
XareltoRivaroxaban12$6,748
Roflumilast33$3,711
Buprenorphine13$3,548
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$1,813
Levothyroxine Sodium198$1,804
Calcitonin-SalmonCalcitonin,salmon,synthetic25$1,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$1,796$57,14680 claims
PfizerEliquis$32$36,16052 claims
Sumitomo Pharma America, Inc.Gemtesa$124$31,03347 claims
Lilly USA, LLCTrulicity$22$23,92917 claims
Boehringer IngelheimJardiance$120$14,78820 claims
NovartisEntresto$48$13,82319 claims
AstraZenecaFarxiga$400$13,25619 claims
AbbVieLinzess$623$8,64112 claims
Johnson & JohnsonXarelto$30$6,74812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →